Challenges for Nanoparticle Characterization

Methods in Molecular Biology

Volumn 697, Issue , 2011, Pages 9-15

  McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

active and passive targeting; efficacy; nanomedicine; Nanoparticles; toxicity

Indexed keywords

NANOMATERIAL; NANOPARTICLE; NEW DRUG;

ARTICLE; CHEMISTRY; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; STANDARD; UNITED STATES;

DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; NANOPARTICLES; NANOSTRUCTURES; REFERENCE STANDARDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955851526     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60327-198-1_2     Document Type: Chapter

References (10)

1. For the remainder of the chapter we confine the discussion to the IND process for drugs regulated through the FDA’s Center for Drug Evaluation and Research (CDER). A similar process is required in the Investigational Device Exemption (IDE) filing for a device regulated through the FDA’s Center for Devices and Radiological Health (CDRH).
2. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjugate Chemistry 2003; 14: 388–394.
3. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 2005; 113: 823–839.
4. Furumoto K, Nagayama S, Ogawara K, Takakura Y, Hashida M, Higaki K, Kimura T. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. Journal of Controlled Release 2004; 97: 133–141.
5. Oberdorster G. Toxicology of ultrafine particles: in vivo studies. Philosophical Transactions of the Royal Society of London Series A, Mathematical Physical and Sciences 2000; 358: 2719–2739.
6. Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M, Takakura Y, Hashida M. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. Journal of Controlled Release 1999; 59: 15–22.
7. Ogawara K, Yoshida M, Kubo J, Nishikawa M, Takakura Y, Hashida M, Higaki K, Kimura T. Mechanisms of hepatic disposition of polystyrene microspheres in rats: effects of serum depend on the sizes of microspheres. Journal of Controlled Release 1999; 61: 241–250.
8. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics 1999; 291: 1017–1022.
9. Rajananthanan P, Attard GS, Sheikh NA, Morrow WJ. Novel aggregate structure adju-vants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice. Vaccine 1999; 18: 140–152.
10. ASTM International Standard Practice F748-98. “Selecting generic biological test methods for materials and devices.”